← Back to all trials
Completed
NCT05180851
A Clinical Study of Recombinant Oncolytic Adenovirus L-IFN Injection With Multiple Administration Routes in Relapsed/Refractory Solid Tumors
Conditions: Head and Neck Cancer, Melanoma, Breast Cancer, Bladder Cancer, Ovarian Carcinoma, Cervical Carcinoma, Lung Cancer
Sex: All
Ages: 18 Years – 75 Years
Healthy volunteers: No
Phase: EARLY_PHASE1
Enrollment: 25
Sponsor: Shanghai Fengxian District Central Hospital
Location: Shanghai Fengxian District Central Hospital Shanghai Shanghai Municipality
Summary
This is an open-label, dose-escalation study evaluating the safety and tolerability of Recombinant Oncolytic Adenovirus L-IFN Injection (YSCH-01) administered via different routes, including intratumoral injection and aerosol therapy, in patients with advanced solid tumors. The purpose of this study is to assess the safety and tolerability of Recombinant L-IFN adenovirus injectionand to determine the recommended phase 1 dose for further study. The study will also evaluate antitumor activity, objective response rate, pharmacokinetics and virus shedding of Recombinant L-IFN adenovirus injection
Eligibility Criteria
Inclusion Criteria:
1. Male or female aged ≥ 18 and ≤ 75 years;
2. Patients with advanced malignant solid tumors, histologically or cytologically confirmed, who have failed standard therapy, have no standard therapy, are not eligible for standard therapy at this stage, or have refused standard therapy;
3. At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1), the length of non-lymph node lesion ≥10 mm or the short diameter of lymph node lesion ≥15 mm according to CT or MRI cross-sectional images;CT scan of the longest axis of measurable lesions ≥10 mm (CT scan thickness ≤5 mm);
4. There were injectable tumor lesions that met the requirements of the current dose group, including superficial lesions and deep lesions that could be injected under the guidance of B-ultrasound /CT;
5. ECOG score of 0 \~ 2;
6. Sufficient hematopoietic capacity: ANC ≥1.0 ×10\^9/L (no short-acting albino within 1 week, no long-acting albino within 2 weeks), platelet count ≥75 ×10\^9/L, HGB \> 80 g/L (no blood transfusion within 2 weeks);
7. Adequate liver and kidney function: AST and ALT ≤3 times ULN in patients without liver metastasis, ≤5 times ULN in patients with liver metastasis; Total bilirubin ≤1.5 ULN (excluding hyperbilirubinemia or hyperbilirubin of non-liver origin);Creatinine ≤2.0 ULN and creatinine clearance and creatinine clearance ≥40 mL/min;
8. Eligible and fertile patients (male and female) must agree to use a reliable contraceptive method during the trial and for at least 90 days after the last dose; Women of childbearing age (15-49 years) must have a negative pregnancy test within 7 days before starting treatment;
9. PT or INR \
Source: ClinicalTrials.gov (NCT05180851). StuddyBuddy aggregates publicly available trial information.